COMPANY

Primmune Therapeutics

Location: Carlsbad, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Melanoma Stage III PRTX007

Raises and deals from press releases

Raise Series B · $8.6M · announced Jan 26, 2026 Company release ↗
Source quote
- Jan 26, 2026 · Company release ↗
  “SAN DIEGO, January 26, 2026 – Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital.”

Raises announced in these releases: $8.6M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jul 1, 2026 Trial start Phase 2: The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma source ↗
Jan 26, 2026 Raise Private equity round — Series B: $8.6M (total, as published), announced Jan 26, 2026. Source: company's own press page. source ↗
Jan 26, 2026 Raise Series B · $8.6M source ↗

2027-12 (ESTIMATED) · Phase 2 · The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma · NCT07565285

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $8.6M. Last 2 years.

Jan 26, 2026 Private equity round — Series B: $8.6M (total, as published), announced Jan 26, 2026. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07565285	The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma	Phase 2	Recruiting	Jul 1, 2026	2027-12 (estimated)